Filing Details

Accession Number:
0001209191-18-052550
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-28 16:11:28
Reporting Period:
2018-09-26
Accepted Time:
2018-09-28 16:11:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1337553 Aerie Pharmaceuticals Inc AERI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252014 J Richard Rubino C/O Aerie Pharmaceuticals, Inc.
4301 Emperor Blvd., Suite 400
Durham NC 27703
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-09-26 49,500 $60.18 334,236 No 4 S Direct
Common Stock Disposition 2018-09-26 500 $61.01 333,736 No 4 S Direct
Common Stock Disposition 2018-09-27 16,497 $60.36 317,239 No 4 S Direct
Common Stock Disposition 2018-09-27 108 $61.01 317,131 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Following the sales reported on this Form 4, the reporting person's Rule 10b5-1 plan dated August 24, 2018 is completed.
  2. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.95, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.05, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $60.00 to $60.90, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.00 to $61.15, inclusive.